Pub Date : 2020-01-01DOI: 10.37421/JIO.2020.S1.009
M. Josa
Breast cancer was the most common cancer in women worldwide in 2018, contributing 25.4% of the total number of cases diagnosed. Evidence says that less than 10% (between 6% and 7%) of the total is due to genetic missfailiures. Some mutations, particularly in BRCA1, BRCA2 and p53 might induce an increase of breast cancer. However, these mutations are rare and account for a small portion of the total breast cancer burden. (1) Risk factors Lifestyle is also determinant when it comes to cancer. Several researches have proven that unhealty diets, obesity (2), smoking (3), alchool intake (4) and a sedentary life style (5) might translate in an increase of all types of cancer risk, including breast cancer (6) Breast cancer prevention According to reserch there are several things that patients can do to prevent all types of cancer, including breast cancer (7),(8), (9) Patient empowerment Research has shown that a healthy lifestyle increases chances to overcome breast cancer. Passing this information on to patients is crucial for them to take an active part in their illness and improve their quality of live as well as their chances to recover health. (10)
{"title":"Breast cancer risk factors, prevention and patients empowerment","authors":"M. Josa","doi":"10.37421/JIO.2020.S1.009","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.009","url":null,"abstract":"Breast cancer was the most common cancer in women worldwide in 2018, contributing 25.4% of the total number of cases diagnosed. Evidence says that less than 10% (between 6% and 7%) of the total is due to genetic missfailiures. Some mutations, particularly in BRCA1, BRCA2 and p53 might induce an increase of breast cancer. However, these mutations are rare and account for a small portion of the total breast cancer burden. (1) Risk factors Lifestyle is also determinant when it comes to cancer. Several researches have proven that unhealty diets, obesity (2), smoking (3), alchool intake (4) and a sedentary life style (5) might translate in an increase of all types of cancer risk, including breast cancer (6) Breast cancer prevention According to reserch there are several things that patients can do to prevent all types of cancer, including breast cancer (7),(8), (9) Patient empowerment Research has shown that a healthy lifestyle increases chances to overcome breast cancer. Passing this information on to patients is crucial for them to take an active part in their illness and improve their quality of live as well as their chances to recover health. (10)","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"95 1","pages":"9-9"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75737784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.37421/JIO.2020.S1.012
S. Canning
Background: Injection of Tc99m to localize nodes for sentinel lymph node biopsy is reported by patients as very painful. The purpose of this study was to determine if anesthetic cream reduces pain associated with periareolar injection of Tc99m and to help elucidate conflicting literature regarding the efficacy of anesthetic cream for this procedure. Methods: A randomized, double-blind, placebo-controlled methodology was used for adult females with breast cancer undergoing periareolar injection of Tc99m for sentinel lymph node biopsy. Pain levels were compared using anesthetic cream (2.5% lidocaine/2.5% prilocaine) vs. placebo. Patient exclusion criteria included use of opioids or adjuvant pain medication or injecting Tc99m the day before surgery. The Numerical Rating Scale was used to assess pain levels immediately after the injections. Results: Comparing 23 experimental and 26 control pa tients, there was no significant difference between the experimental (median = 4) and the control group (median = 5) on level of pain experienced U=0.492, P > .05. Conclusions: The experimental group had a slightly lower median pain score; however, there was no statistically significant difference between those who used the cream compared with those who used a placebo, supporting the conclusion that anesthetic cream does not reduce pain during Tc99m injections. This study adds to the current literature to provide a stronger position that there is no benefit to using anesthetic cream for this procedure.
背景:患者报告，在前哨淋巴结活检中注射Tc99m定位淋巴结是非常痛苦的。本研究的目的是确定麻醉药膏是否能减轻与乳晕周围注射Tc99m相关的疼痛，并帮助阐明有关麻醉药膏在该手术中的疗效的相互矛盾的文献。方法:采用随机、双盲、安慰剂对照的方法，对成年女性乳腺癌患者行乳晕周围注射Tc99m前哨淋巴结活检。比较使用麻醉膏(2.5%利多卡因/2.5%普丙罗卡因)和安慰剂的疼痛水平。患者排除标准包括术前使用阿片类药物或辅助止痛药或注射Tc99m。注射后立即使用数值评定量表评估疼痛程度。结果:实验组23例与对照组26例比较，实验组(中位数= 4)与对照组(中位数= 5)疼痛程度差异无统计学意义(U=0.492, P > 0.05)。结论:实验组患者疼痛中位评分略低;然而，与使用安慰剂的患者相比，使用该药膏的患者之间没有统计学上的显著差异，这支持了麻醉药膏不能减轻注射Tc99m时疼痛的结论。这项研究增加了现有文献，提供了一个更强有力的立场，即在此过程中使用麻醉膏没有好处。
{"title":"Effect of Topical Anesthetic Cream on Pain During Periareolar Injection of Technetium Tc99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer: A Randomized Control Trial","authors":"S. Canning","doi":"10.37421/JIO.2020.S1.012","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.012","url":null,"abstract":"Background: Injection of Tc99m to localize nodes for sentinel lymph node biopsy is reported by patients as very painful. The purpose of this study was to determine if anesthetic cream reduces pain associated with periareolar injection of Tc99m and to help elucidate conflicting literature regarding the efficacy of anesthetic cream for this procedure. Methods: A randomized, double-blind, placebo-controlled methodology was used for adult females with breast cancer undergoing periareolar injection of Tc99m for sentinel lymph node biopsy. Pain levels were compared using anesthetic cream (2.5% lidocaine/2.5% prilocaine) vs. placebo. Patient exclusion criteria included use of opioids or adjuvant pain medication or injecting Tc99m the day before surgery. The Numerical Rating Scale was used to assess pain levels immediately after the injections. Results: Comparing 23 experimental and 26 control pa tients, there was no significant difference between the experimental (median = 4) and the control group (median = 5) on level of pain experienced U=0.492, P > .05. Conclusions: The experimental group had a slightly lower median pain score; however, there was no statistically significant difference between those who used the cream compared with those who used a placebo, supporting the conclusion that anesthetic cream does not reduce pain during Tc99m injections. This study adds to the current literature to provide a stronger position that there is no benefit to using anesthetic cream for this procedure.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"1 1","pages":"12-12"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79482653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.37421/JIO.2020.S1.007
Major, Koyabe, Ntsayagae, Molwane, Monare
There is evidence of ongoing research and investment in Africa to improve vaccination, screening, and treatment for cervical cancer (Finocchario-Kessler , Wexler , Maloba , Mabachi , Ndikum-Moffor , Bukusi; 2016). However, the majority (54.6 %) of cervical cancer research in Africa focused on secondary prevention (i.e., screening). This is followed by studies focusing on primary prevention (23.4 %) of cervical cancer, particularly HPV vaccination. Finocchario-Kessler, etc (2016) records that research focusing on tertiary prevention, which is the treatment of cervical cancer, is at the lowest (17.6 %). It is vital that research focusing on tertiary prevention for women diagnosed with abnormal cervical tissue is given equal attention as a matter of urgency for the overall survival (OS) for women with locally advanced cervical cancer. Studies on adherence to treatment regimen and schedule for cervical cancer will inform the innovation and improvement efforts towards treatment adherence and follow-up of women diagnosed with abnormal cervical tissue.
{"title":"Evaluation of predictors for behavioral intentions to adhere to cervical cancer treatment among aged 25-49 years in Botswana.","authors":"Major, Koyabe, Ntsayagae, Molwane, Monare","doi":"10.37421/JIO.2020.S1.007","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.007","url":null,"abstract":"There is evidence of ongoing research and investment in Africa to improve vaccination, screening, and treatment for cervical cancer (Finocchario-Kessler , Wexler , Maloba , Mabachi , Ndikum-Moffor , Bukusi; 2016). However, the majority (54.6 %) of cervical cancer research in Africa focused on secondary prevention (i.e., screening). This is followed by studies focusing on primary prevention (23.4 %) of cervical cancer, particularly HPV vaccination. Finocchario-Kessler, etc (2016) records that research focusing on tertiary prevention, which is the treatment of cervical cancer, is at the lowest (17.6 %). It is vital that research focusing on tertiary prevention for women diagnosed with abnormal cervical tissue is given equal attention as a matter of urgency for the overall survival (OS) for women with locally advanced cervical cancer. Studies on adherence to treatment regimen and schedule for cervical cancer will inform the innovation and improvement efforts towards treatment adherence and follow-up of women diagnosed with abnormal cervical tissue.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"137 1","pages":"7-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79702399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We’re pleased to bring you exciting news about next year’s “Global Summit On Oncology and Breast Cancer ”.Which is going to held on March 05-06, 2020 | Vienna, Austria . We have set a date and location that we hope for the foundation of a productive and enjoyable gathering. Oncology 2020 regards each one of the individuals to go to the “Oncology 2020” amidst March 05-06, 2020. which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops, Speaker sessions. Oncology 2020 will join world-class professors, scientists, researchers, students, Perfusionists, Oncologists to discuss methodology for ailment remediation for Cancer diseases, Breast Cancer and health disorders. Oncology 2020 are planned to give various information that will keep helpful specialists next to each other of the issues impacting the expectations, finding and treatment of Cancer diseases. The assembling of this event will be dealt with around the subject “Oncology 2020”.
{"title":"Global Summit On Oncology and Breast Cancer | March 05-06, 2020 | Vienna, Austria","authors":"N. Senhou","doi":"10.37421/JIO.2020.S1.01","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.01","url":null,"abstract":"We’re pleased to bring you exciting news about next year’s “Global Summit On Oncology and Breast Cancer ”.Which is going to held on March 05-06, 2020 | Vienna, Austria . We have set a date and location that we hope for the foundation of a productive and enjoyable gathering. Oncology 2020 regards each one of the individuals to go to the “Oncology 2020” amidst March 05-06, 2020. which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops, Speaker sessions. Oncology 2020 will join world-class professors, scientists, researchers, students, Perfusionists, Oncologists to discuss methodology for ailment remediation for Cancer diseases, Breast Cancer and health disorders. Oncology 2020 are planned to give various information that will keep helpful specialists next to each other of the issues impacting the expectations, finding and treatment of Cancer diseases. The assembling of this event will be dealt with around the subject “Oncology 2020”.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"21 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84817014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-25DOI: 10.4172/2329-6771-c3-008
pFabio Fanfonip
{"title":"Evaluation of endoscopic balloon dilatation as a treatment of eustachian tube dysfunction","authors":"pFabio Fanfonip","doi":"10.4172/2329-6771-c3-008","DOIUrl":"https://doi.org/10.4172/2329-6771-c3-008","url":null,"abstract":"","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89186057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.4172/2329-6771.1000222
Wilasinee Areeruk, T. Manchana
Objective: To evaluate the correlation between squamous cell abnormalities by liquid-based cytology and histopathology, and to evaluate the accuracy of liquid-based cytology in detecting cervical squamous cell abnormalities.Methods: A total of 943 patients with squamous cell abnormalities by liquid-based cytology underwent colposcopic examination from June 2014 until May 2017. The final histopathology was defined as the most severe lesion from colposcopic directed biopsy, excision procedure or hysterectomy.Results: A majority of abnormal cytology was LSIL (45.6%), followed by ASCUS, HSIL, ASC-H and SCC (29.6%, 13.5%, 9.7%, and 1.7%, respectively). LSIL/ASCUS cytology was confirmed to be CIN1 or less in approximately 90% of patients but coexisting high-grade lesions (CIN2/3) occurred in about 10% and invasive cancer was less than 1%. HSIL and ASC-H cytology yielded about 50% and 25% high-grade lesions, respectively; coexisting invasive cancer was diagnosed in 10.2% and 1.1%, respectively. Invasive cancers were diagnosed in 43.8% of patients with SCC cytology. The accuracy of liquid-based cytology for detecting cervical squamous cell abnormalities was 79.8%. There was a moderate correlation between cervical cytology and histopathology (Kappa=0.43, 95% CI=0.36-0.50).Conclusion: The correlation between cervical cytology and histopathology remained moderate. Despite, acceptable accuracy rate, it should only be used as a screening test. About 10% of the high-grade lesion was found in low-grade cytology and 10% of invasive lesion co-existed in high-grade cytology. Therefore, pathological confirmation should be made before definitive management especially in areas with high incidence of cervical cancers.
{"title":"The Correlation between Squamous Cell Abnormalities by Liquid based Cytology and Histopathology","authors":"Wilasinee Areeruk, T. Manchana","doi":"10.4172/2329-6771.1000222","DOIUrl":"https://doi.org/10.4172/2329-6771.1000222","url":null,"abstract":"Objective: To evaluate the correlation between squamous cell abnormalities by liquid-based cytology and histopathology, and to evaluate the accuracy of liquid-based cytology in detecting cervical squamous cell abnormalities.Methods: A total of 943 patients with squamous cell abnormalities by liquid-based cytology underwent colposcopic examination from June 2014 until May 2017. The final histopathology was defined as the most severe lesion from colposcopic directed biopsy, excision procedure or hysterectomy.Results: A majority of abnormal cytology was LSIL (45.6%), followed by ASCUS, HSIL, ASC-H and SCC (29.6%, 13.5%, 9.7%, and 1.7%, respectively). LSIL/ASCUS cytology was confirmed to be CIN1 or less in approximately 90% of patients but coexisting high-grade lesions (CIN2/3) occurred in about 10% and invasive cancer was less than 1%. HSIL and ASC-H cytology yielded about 50% and 25% high-grade lesions, respectively; coexisting invasive cancer was diagnosed in 10.2% and 1.1%, respectively. Invasive cancers were diagnosed in 43.8% of patients with SCC cytology. The accuracy of liquid-based cytology for detecting cervical squamous cell abnormalities was 79.8%. There was a moderate correlation between cervical cytology and histopathology (Kappa=0.43, 95% CI=0.36-0.50).Conclusion: The correlation between cervical cytology and histopathology remained moderate. Despite, acceptable accuracy rate, it should only be used as a screening test. About 10% of the high-grade lesion was found in low-grade cytology and 10% of invasive lesion co-existed in high-grade cytology. Therefore, pathological confirmation should be made before definitive management especially in areas with high incidence of cervical cancers.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84368927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-24DOI: 10.4172/2329-6771.1000208
G. Zugmaier, A. Karalis, C. Knabbe, A. Aigner
Introduction: The secreted growth factor pleiotrophin (PTN) belongs to the midkine family of heparin-binding growth factors and is tightly regulated during embryogenesis. In contrast to its very limited expression in normal adult tissues, PTN protein levels are markedly increased in different tumors, with PTN showing mitogenic, chemotactic, transforming, pro-angiogenic, pro-invasive and pro-metastatic activity. However, little is known about PTN upregulation in diseases other than cancer. The aim of this study was to investigate PTN serum levels in patients with various non-malignant chronic or acute disorders, and in pregant women, compared to healthy nonpregnant blood donors as negative control group.Materials and Methods: PTN serum levels were determined by a sandwich ELISA.Results: PTN serum levels were found to be significantly elevated with a p-value of <0.05 in patients with the acute non-malignant disorders, acute inflammation, acute vascular disease and acute trauma. In patients with chronic leukemia and solid tumors, and pregnancy, increased PTN serum levels were detected as well.Conclusion: Beyond its described functions in solid tumors and in the central nervous system, these data indicate that PTN is an acute phase protein in the adult organism and that, due to its upregulation under various non-cancer conditions, special caution must be taken when exploring PTN serum levels as potential tumor marker.
{"title":"Pilot Screening Study of the Angiogenesis Factor Pleiotrophin (PTN) in Serum Samples from Patients of Various Disease Groups","authors":"G. Zugmaier, A. Karalis, C. Knabbe, A. Aigner","doi":"10.4172/2329-6771.1000208","DOIUrl":"https://doi.org/10.4172/2329-6771.1000208","url":null,"abstract":"Introduction: The secreted growth factor pleiotrophin (PTN) belongs to the midkine family of heparin-binding growth factors and is tightly regulated during embryogenesis. In contrast to its very limited expression in normal adult tissues, PTN protein levels are markedly increased in different tumors, with PTN showing mitogenic, chemotactic, transforming, pro-angiogenic, pro-invasive and pro-metastatic activity. However, little is known about PTN upregulation in diseases other than cancer. The aim of this study was to investigate PTN serum levels in patients with various non-malignant chronic or acute disorders, and in pregant women, compared to healthy nonpregnant blood donors as negative control group.Materials and Methods: PTN serum levels were determined by a sandwich ELISA.Results: PTN serum levels were found to be significantly elevated with a p-value of <0.05 in patients with the acute non-malignant disorders, acute inflammation, acute vascular disease and acute trauma. In patients with chronic leukemia and solid tumors, and pregnancy, increased PTN serum levels were detected as well.Conclusion: Beyond its described functions in solid tumors and in the central nervous system, these data indicate that PTN is an acute phase protein in the adult organism and that, due to its upregulation under various non-cancer conditions, special caution must be taken when exploring PTN serum levels as potential tumor marker.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"8 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2018-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74300691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-03-25DOI: 10.4172/2329-6771.1000206
H. Govardhan, N. Nelson, Khaleel, M. Roy
Background: Prior research reveal the benefits of yoga in managing fatigue, stress and psychosocial outcomes in cervical carcinoma; however, a definite structured yoga program is unavailable. In this study an effort is made to develop and validate a structured yoga program for cervical carcinoma. Methods: A detailed review of ancient and contemporary yoga literature was conducted to design a basic yoga program. Five yoga experts, who fulfilled the inclusion criteria validated the program. 27 practices were rated as (i) not essential, (ii) useful but not essential, and (iii) essential; Lawshe's content validity ratio (CVR) was calculated. Results: Eighteen practices exhibited significant content validity (cut-off value: 0.99, as calculated by applying Lawshe's formula for the CVR). One practice was added to the module by the experts, making a total of 19 practices including meditation. Yoga nidra was added as a special practice on days of high fatigue. Conclusions: The designed program received good content validity and thus is valid for cervical cancer. The program is to be applied on patients to assess its acceptability and feasibility.
{"title":"Development of Comprehensive Yoga Program for Cervical Carcinoma","authors":"H. Govardhan, N. Nelson, Khaleel, M. Roy","doi":"10.4172/2329-6771.1000206","DOIUrl":"https://doi.org/10.4172/2329-6771.1000206","url":null,"abstract":"Background: Prior research reveal the benefits of yoga in managing fatigue, stress and psychosocial outcomes in cervical carcinoma; however, a definite structured yoga program is unavailable. In this study an effort is made to develop and validate a structured yoga program for cervical carcinoma. \u0000Methods: A detailed review of ancient and contemporary yoga literature was conducted to design a basic yoga program. Five yoga experts, who fulfilled the inclusion criteria validated the program. 27 practices were rated as (i) not essential, (ii) useful but not essential, and (iii) essential; Lawshe's content validity ratio (CVR) was calculated. \u0000Results: Eighteen practices exhibited significant content validity (cut-off value: 0.99, as calculated by applying Lawshe's formula for the CVR). One practice was added to the module by the experts, making a total of 19 practices including meditation. Yoga nidra was added as a special practice on days of high fatigue. \u0000Conclusions: The designed program received good content validity and thus is valid for cervical cancer. The program is to be applied on patients to assess its acceptability and feasibility.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"57 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2018-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80917175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-08DOI: 10.4172/2329-6771.1000I101
Baroni Adone
A 78-year-old woman presented with a 2-month-history of a cutaneous red nodule on her left leg (Figure 1). Differential diagnosis of nodular red lesions includes dermal nevus, pyogenic granuloma, angioma, amelanotic melanoma, eccrine poroma, Kaposi’s sarcoma, skin metastasis etc.
{"title":"A Red Skin Nodule","authors":"Baroni Adone","doi":"10.4172/2329-6771.1000I101","DOIUrl":"https://doi.org/10.4172/2329-6771.1000I101","url":null,"abstract":"A 78-year-old woman presented with a 2-month-history of a cutaneous red nodule on her left leg (Figure 1). Differential diagnosis of nodular red lesions includes dermal nevus, pyogenic granuloma, angioma, amelanotic melanoma, eccrine poroma, Kaposi’s sarcoma, skin metastasis etc.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"26 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2018-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90285148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-03DOI: 10.4172/2329-6771.1000202
A. Mackawy, O. Megahed
Background: Multiple genes are known to influence the cancer metastasis but the effect of the germline heritable genetic polymorphisms on the predisposition and metastasis is not yet well known. Signal-induced proliferation associated gene1 (SIPA1) was considered as a modifying factor in the breast carcinoma (BC) metastasis process. Molecular studies on Sipa 1 gene suggested its essential role as cell adhesion regulator and metastasis modulator. The present study relied on the hypothesis that Sipa1 gene may be contributed to the risk of breast cancer occurrence and aggressiveness as well.Objective: We aimed to examine the association of SIPA1 single nucleotide polymorphisms (SNPs) and human breast cancer incidence and prognosis in Egyptian female patients.Patient and Methods: Two common SNPs (rs3741378 C>T and rs746429 A>G) were genotyped in 80 Egyptian females; 50 patients with breast cancer and 30 breast carcinoma free females.Results: The rs3741378 TT genotype enhanced the incidence of breast carcinoma in comparison with the genotypes rs3741378 CC and TC (X2=7.08, P=0.029), Sipa 1 rs3741378 T allele had a high frequency in BC cases compared to controls (OR (95%)=2.593 (1.339-5.02), P=0.04). Sipa 1 rs3741378 TT genotype also displayed significant association with clinical stages, grades and lymph node metastasis (X2=12.73, P=0.013), (X2=10.88, P=0.028), (X2=6.534, P=0.010; OR (95%)=0.324 [0.134-0.781]), respectively. Pointing to those patients carrying the rs3741378 TT genotype had a higher tumor progression rate with advanced tumor grades. Oppositely, these associations could not be detected for rs746429 A>G.Conclusion: Our results suggest that the Sipa1 promoter rs3741378 C>T SNP was contributed to BC risk and progression, which may be considered as a foretelling biomarker of BC risk and progression.
{"title":"SIPA1 Gene Polymorphisms And The Risk Of Breast Carcinoma Among The Egyptian Females: A Pilot Study","authors":"A. Mackawy, O. Megahed","doi":"10.4172/2329-6771.1000202","DOIUrl":"https://doi.org/10.4172/2329-6771.1000202","url":null,"abstract":"Background: Multiple genes are known to influence the cancer metastasis but the effect of the germline heritable genetic polymorphisms on the predisposition and metastasis is not yet well known. Signal-induced proliferation associated gene1 (SIPA1) was considered as a modifying factor in the breast carcinoma (BC) metastasis process. Molecular studies on Sipa 1 gene suggested its essential role as cell adhesion regulator and metastasis modulator. The present study relied on the hypothesis that Sipa1 gene may be contributed to the risk of breast cancer occurrence and aggressiveness as well.Objective: We aimed to examine the association of SIPA1 single nucleotide polymorphisms (SNPs) and human breast cancer incidence and prognosis in Egyptian female patients.Patient and Methods: Two common SNPs (rs3741378 C>T and rs746429 A>G) were genotyped in 80 Egyptian females; 50 patients with breast cancer and 30 breast carcinoma free females.Results: The rs3741378 TT genotype enhanced the incidence of breast carcinoma in comparison with the genotypes rs3741378 CC and TC (X2=7.08, P=0.029), Sipa 1 rs3741378 T allele had a high frequency in BC cases compared to controls (OR (95%)=2.593 (1.339-5.02), P=0.04). Sipa 1 rs3741378 TT genotype also displayed significant association with clinical stages, grades and lymph node metastasis (X2=12.73, P=0.013), (X2=10.88, P=0.028), (X2=6.534, P=0.010; OR (95%)=0.324 [0.134-0.781]), respectively. Pointing to those patients carrying the rs3741378 TT genotype had a higher tumor progression rate with advanced tumor grades. Oppositely, these associations could not be detected for rs746429 A>G.Conclusion: Our results suggest that the Sipa1 promoter rs3741378 C>T SNP was contributed to BC risk and progression, which may be considered as a foretelling biomarker of BC risk and progression.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"43 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2018-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88553722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：